Stock Analiz

Protagonist Therapeutics, Inc (PTGX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$130M, a net margin of -282.8%; the best year in this period was 2024 with $275M.

Free cash flow was $56M in fiscal 2025 and positive in 3 of the 10 years shown.

The diluted share count rose 878% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $20M172018: $31M182019: $231000192020: $29M202021: $27M212022: $27M222023: $60M232024: $434M242025: $46M25$46M
Net income
2016: -$37M162017: -$37M172018: -$39M182019: -$77M192020: -$66M202021: -$126M212022: -$127M222023: -$79M232024: $275M242025: -$130M25-$130M
Free cash flow
2016: -$30M162017: $3M172018: -$50M182019: -$42M192020: -$73M202021: -$109M212022: -$109M222023: -$71M232024: $183M242025: $56M25$56M
EPS (diluted)
2016: $-5.80162017: $-2.09172018: $-1.74182019: $-2.98192020: $-1.92202021: $-2.71212022: $-2.60222023: $-1.39232024: $4.23242025: $-2.0525$-2.05

Income statement

Fiscal year2025202420232022202120202019201820172016
Revenue$46M$434M$60M$27M$27M$29M$231000$31M$20M—
Gross profit——————————
Operating income-$158M$253M-$94M-$131M-$126M-$65M-$81M-$42M-$38M-$33M
Net income-$130M$275M-$79M-$127M-$126M-$66M-$77M-$39M-$37M-$37M
EPS (diluted)$-2.05$4.23$-1.39$-2.60$-2.71$-1.92$-2.98$-1.74$-2.09$-5.80
R&D$159M$138M$120M$126M$126M$75M$65M$59M$46M$26M
Revenue growth−89.4%+624.0%+125.7%−2.8%−4.4%+12293.1%−99.2%+54.1%——

Cash flow

Fiscal year2025202420232022202120202019201820172016
Operating cash flow$58M$184M-$70M-$108M-$108M-$72M-$42M-$50M$4M-$30M
Capital spending-$2M-$1M-$609000-$795000-$1M-$471000-$967000-$486000-$666000-$347000
Free cash flow$56M$183M-$71M-$109M-$109M-$73M-$42M-$50M$3M-$30M
Dividends paid$0$0$0$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay$46M$38M$29M$24M$16M$8M$8M$7M$4M$2M

Balance sheet

Fiscal year2025202420232022202120202019201820172016
Cash$567M$419M$342M$237M$327M$306M$133M$129M$106M$21M
Debt$10M$11M$1M$4M$6M$6M$17M———
Equity$615M$675M$337M$216M$300M$280M$80M$113M$121M$88M
Total assets$668M$745M$358M$248M$348M$324M$155M$139M$164M$94M
Shares (diluted)64M65M57M49M46M34M26M22M18M7M

Margins and returns

Fiscal year2025202420232022202120202019201820172016
Gross margin——————————
Operating margin-343.6%58.2%-156.1%-494.2%-460.0%-225.4%-34857.6%-136.7%-188.9%—
Net margin-282.8%63.3%-131.6%-479.3%-458.9%-231.1%-33414.3%-125.9%-184.2%—
FCF margin121.9%42.1%-118.1%-409.8%-398.3%-254.8%-18395.7%-163.1%16.0%—
ROIC-20.0%36.3%-27.7%-59.9%-41.1%-17.8%-82.3%-36.8%-31.4%-37.3%
ROE-21.2%40.8%-23.4%-59.1%-41.9%-23.7%-96.5%-34.6%-30.6%-42.5%

Frequently asked questions

What is Protagonist Therapeutics’s annual revenue?

$46M in fiscal 2025.

How much profit does Protagonist Therapeutics make?

Net income was -$130M in fiscal 2025 (net margin -282.8%).

Is Protagonist Therapeutics’s revenue growing?

No: revenue fell 89.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.